Centene Corporation
CNC
$63.14
-0.85%
Centene Corporation is a leading managed care organization specializing in government-sponsored healthcare plans, primarily Medicaid, Medicare, and individual exchange offerings under the Affordable Care Act. The company is a dominant player in the Medicaid managed care market, serving approximately 20 million members, which provides a stable, recurring revenue base tied to public health programs. The current investor narrative is dominated by a strategic pivot toward profitability following a significant loss in Affordable Care Act membership, as evidenced by recent news of voluntary staff buyouts to cut costs, juxtaposed against a favorable sector tailwind from increased Medicare Advantage payments which has boosted sentiment across managed care stocks.…
CNC
Centene Corporation
$63.14
Related headlines
Investment Opinion: Should I buy CNC Today?
Rating & Thesis: Hold. Centene is a high-risk, high-potential turnaround story where the extreme valuation discount is balanced by severe fundamental challenges, warranting a neutral stance until profitability stabilizes. This aligns with the analyst consensus of 'Neutral' or 'Equal Weight'.
Supporting Evidence: The primary valuation metric, the forward PS ratio of 0.095, represents a 74% discount to the industry average of 0.406, suggesting significant upside if the company recovers. Revenue growth remains robust at 21.86% YoY, and the company generates substantial free cash flow of $4.32B. However, profitability is deeply negative, with a net margin of -3.4% and an operating margin of -3.5%. The stock's 77% three-month rally has significantly reduced the margin of safety from a technical perspective.
Risks & Conditions: The two biggest risks are the failure to achieve consistent profitability and a reversal of the recent positive momentum. This Hold rating would upgrade to a Buy if the company reports two consecutive quarters of positive net income and the PS ratio remains below 0.15. It would downgrade to a Sell if quarterly losses widen beyond the Q4 2025 level or if revenue growth turns negative. Relative to its history and peers, the stock is deeply undervalued on a sales basis but fairly valued (or even overvalued) on an earnings basis given the current losses.
Sign up to view all
CNC 12-Month Price Forecast
The analysis adopts a neutral stance based on the high-conviction conflict between valuation and fundamentals. The deep sales multiple discount and strong cash flow are compelling, but they are directly countered by severe, volatile losses and an uncertain turnaround path. Confidence is medium because the recent powerful price momentum suggests the market is beginning to price in a recovery, but the lack of analyst upgrades indicates professional skepticism remains. The stance would upgrade to bullish on confirmation of sustained quarterly profitability (net income > $0). It would downgrade to bearish if losses re-widen or the stock breaks below key technical support at $50.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Centene Corporation's 12-month outlook, with a consensus price target around $82.08 and implied upside of +30.0% versus the current price.
Average Target
$82.08
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$51 - $82
Analyst target range
Analyst coverage appears limited with only 5 analysts providing estimates, indicating this may be a less-followed large-cap name or that coverage has condensed. The consensus sentiment, inferred from recent institutional ratings, is neutral to cautiously optimistic, with firms like JP Morgan, Mizuho, and Morgan Stanley maintaining 'Neutral' or 'Equal Weight' stances, though Barclays upgraded to 'Overweight' in January 2026. The average revenue target for the forward period is $213.12 billion, with a range from $208.08 billion to $218.24 billion, showing a relatively tight spread of about 4.8%, which suggests moderate conviction in the near-term revenue outlook. The pattern of recent ratings shows stability, with no downgrades in the provided data and one upgrade, hinting that the worst of the operational challenges may be priced in, but analysts await clearer signs of sustained execution on the path to profitability before becoming more bullish.
Bulls vs Bears: CNC Investment Factors
The investment debate for Centene is a classic battle between deep value and broken fundamentals. The bull case, currently supported by stronger evidence from the powerful price momentum and extreme valuation discount, argues that the market has over-penalized a company with a dominant market position and strong cash flow. The bear case rightly highlights the severe and ongoing profitability crisis, which makes traditional valuation metrics like P/E meaningless. The single most important tension is whether management's strategic pivot toward profitability—evidenced by cost-cutting and narrowing losses—can be executed before the valuation discount closes. If profitability returns, the upside from a PS ratio re-rating toward the sector average is substantial. If losses persist or worsen, the stock could retest its lows despite the recent rally.
Bullish
- Deep Valuation Discount to Sector: Centene trades at a forward Price-to-Sales (PS) ratio of 0.095, a 74% discount to the industry average PS of 0.406. This extreme discount suggests the market has priced in significant pessimism, creating a wide margin of safety if the company's strategic pivot succeeds.
- Strong Revenue Growth and Market Position: Q4 2025 revenue grew 21.86% year-over-year to $49.73 billion, driven by its dominant Medicaid segment ($37.65B). The company's 20 million member base provides a stable, recurring revenue foundation tied to government-sponsored healthcare programs.
- Robust Free Cash Flow Generation: Despite net losses, the company generated $4.32 billion in trailing twelve-month free cash flow. This strong cash generation provides ample internal resources to fund operations and navigate its turnaround without excessive reliance on debt or equity markets.
- Powerful Technical Recovery Momentum: The stock has surged 77.38% over the past three months, significantly outperforming the S&P 500's 15.14% gain. Trading at 92% of the distance from its 52-week low to high ($25.08 to $66.55) signals strong buying momentum and a decisive reversal of prior weakness.
Bearish
- Severe and Volatile Profitability Crisis: The company reported a net loss of $1.10 billion in Q4 2025, following a catastrophic $6.63 billion loss in Q3 2025. Operating margin improved but remains negative at -3.5%, indicating the core business is still not sustainably profitable.
- ACA Membership Slump Driving Cost Cuts: Recent news confirms a significant loss in Affordable Care Act membership, forcing the company into voluntary staff buyouts to cut costs. This signals near-term revenue pressure in its Commercial segment, which contributed $10.79 billion in Q4.
- Valuation Discount Reflects Fundamental Risk: The stock's PS ratio of 0.10 is near the absolute bottom of its multi-year historical range (high of 1.48). This deep discount is justified by its negative net margin of -3.4% and ROE of -33.4%, reflecting a broken earnings model.
- Analyst Sentiment Remains Cautiously Neutral: With only 5 analysts providing estimates, coverage is limited. The consensus stance is neutral, with firms like JP Morgan and Morgan Stanley maintaining 'Neutral' ratings, indicating professional skepticism about the sustainability of the recent rally.
CNC Technical Analysis
The stock is in a powerful recovery trend, having surged 77.38% over the past three months, decisively reversing a longer-term period of weakness indicated by a modest 1-year gain of 10.64%. As of the latest close of $61.02, the stock is trading near the top of its 52-week range, approximately 92% of the distance from its low of $25.08 to its high of $66.55, signaling strong momentum but also potential overextension. Recent momentum is exceptionally strong, with a 3.16% gain over the past month, which significantly outpaces the S&P 500's 0.74% gain, as shown by the relative strength of 2.42, indicating the stock is leading the market's recent advance. The stock's beta of 1.093 suggests it is moderately more volatile than the broader market, which is typical for a managed care company subject to regulatory and reimbursement policy shifts. Key technical support is anchored at the 52-week low of $25.08, while immediate resistance sits at the 52-week high of $66.55; a decisive breakout above this level would confirm the strength of the current recovery and potentially open the door to further gains, whereas a failure could signal a consolidation phase after the sharp rally.
Beta
1.09
1.09x market volatility
Max Drawdown
-59.3%
Largest decline past year
52-Week Range
$25-$67
Price range past year
Annual Return
+18.2%
Cumulative gain past year
| Period | CNC Return | S&P 500 |
|---|---|---|
| 1m | +6.8% | -1.6% |
| 3m | +92.9% | +11.7% |
| 6m | +58.3% | +6.3% |
| 1y | +18.2% | +22.2% |
| ytd | +51.1% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CNC Fundamental Analysis
Revenue growth is robust but volatile on a quarterly basis; the most recent Q4 2025 revenue was $49.73 billion, representing a 21.86% year-over-year increase, yet this follows a tumultuous pattern where Q1 2025 showed strong profitability but Q3 2025 saw a massive net loss. The Medicaid segment is the primary driver, contributing $37.65 billion, while the Commercial segment, which includes ACA exchange plans, contributed $10.79 billion and is the source of recent membership pressures. Profitability is highly inconsistent, with the company reporting a net loss of $1.10 billion and a gross margin of 15.18% in Q4 2025, but this was a significant improvement from the Q3 2025 net loss of $6.63 billion and gross margin of 16.38%, indicating the loss is narrowing. The operating margin was negative at -3.5% in Q4, an improvement from -13.99% in Q3, suggesting management's cost-cutting efforts may be starting to stabilize operations. The balance sheet shows a manageable debt-to-equity ratio of 0.94, and the company maintains strong liquidity with a current ratio of 1.68. Crucially, the company generates substantial operating cash flow, with $4.32 billion in trailing twelve-month free cash flow, providing ample internal resources to fund operations and navigate the current transition without excessive reliance on external financing.
Quarterly Revenue
$49.7B
2025-12
Revenue YoY Growth
+0.21%
YoY Comparison
Gross Margin
+0.15%
Latest Quarter
Free Cash Flow
$4.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CNC Overvalued?
Given the negative net income of -$1.10 billion in the latest quarter, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 0.104, while the forward PS, implied by the market cap of $20.21 billion and analyst revenue estimate of $213.12 billion, is approximately 0.095, indicating the market expects modest revenue growth and potentially improved efficiency. Compared to the provided industry average PS ratio of 0.406 from the historical Q4 2025 data, Centene's current PS of 0.104 represents a steep 74% discount to its own recent historical sector multiple, suggesting the market is pricing in significant skepticism or assigning a lower multiple due to its profitability challenges. Historically, the stock's own PS ratio has fluctuated significantly, from a high of 1.48 in late 2021 to the current 0.10; trading near the absolute bottom of its multi-year historical range indicates the market has deeply discounted the shares, which could represent a value opportunity if the company's turnaround towards consistent profitability gains traction.
PE
-3.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -72x~220x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-4.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Centene's primary risk is its severe profitability crisis, with a net loss of $1.10 billion in Q4 2025 and a gross margin of only 15.18%. The company's revenue is heavily concentrated in government-sponsored plans, making it vulnerable to reimbursement rate changes and regulatory shifts. While the debt-to-equity ratio of 0.94 is manageable, the negative ROE of -33.4% indicates shareholder equity is being eroded. The recent voluntary staff buyouts highlight operational stress from a slump in ACA membership, creating near-term execution risk as the company cuts costs to stabilize margins.
Market & Competitive Risks: The stock's 77% surge over three months has pushed it to trade at 92% of its 52-week high, increasing the risk of a sharp pullback if the turnaround narrative falters. While the PS ratio is at a deep discount, this reflects justified skepticism about its earnings model compared to profitable peers. The stock's beta of 1.093 indicates above-market volatility, sensitive to sector news like Medicare Advantage payment changes. Competitive risks are high in the managed care sector, where scale and efficiency are critical, and Centene's recent losses may hinder its ability to invest competitively.
Worst-Case Scenario: The worst-case scenario involves the company failing to stem losses, leading to further membership declines, credit rating downgrades, and a loss of investor confidence. A return to the catastrophic Q3 2025 loss levels could trigger analyst downgrades and force a dilutive capital raise. Realistic downside could see the stock retracing a significant portion of its recent rally, potentially falling back toward its 52-week low of $25.08. From the current price of $61.02, this represents a downside of approximately -59%, aligning with the stock's historical max drawdown of -59.31%.
FAQ
The key risks are, in order of severity: 1) Profitability Risk: The company is not consistently profitable, with a net margin of -3.4% and a catastrophic $6.63B loss in Q3 2025. 2) Operational Risk: Recent news of staff buyouts highlights stress from a slump in Affordable Care Act membership, pressuring revenue. 3) Valuation & Momentum Risk: The stock has surged 77% in three months and trades near its 52-week high, increasing vulnerability to a pullback. 4) Market Risk: With a beta of 1.093, the stock is more volatile than the market and sensitive to sector-specific regulatory changes.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $55 and $70 as losses narrow but volatility continues. The Bull Case (25% probability) targets $70 to $85 on a successful profitability turnaround and PS ratio re-rating. The Bear Case (15% probability) warns of a drop to $25-$40 if losses re-widen. The most likely scenario is the Base Case, which assumes the company's recovery remains uneven and the stock consolidates after its sharp rally. The key assumption is that quarterly losses continue to narrow but do not turn positive in the near term.
CNC is deeply undervalued on a sales basis but lacks a meaningful earnings-based valuation due to losses. Its forward Price-to-Sales (PS) ratio of 0.095 is 74% below the industry average of 0.406, suggesting significant undervaluation if profitability normalizes. Historically, its own PS ratio has been as high as 1.48, indicating the current 0.10 level is at an extreme low. The market is pricing in a deeply discounted scenario where profitability challenges persist. Therefore, it is undervalued relative to peers and its own history, but this discount is justified by its current broken earnings model.
CNC is a high-risk, high-potential investment that may be a good buy only for speculative, risk-tolerant investors with a long-term horizon. The 74% discount to the sector's average PS ratio offers substantial upside if the company returns to profitability, as evidenced by its $4.32B in annual free cash flow. However, the severe quarterly losses, including a $1.10B net loss in Q4 2025, and the recent 77% price surge increase near-term risk. It is not a good buy for conservative investors seeking stability or income.
CNC is suitable only for long-term investment with a minimum horizon of 2-3 years. The company's turnaround from significant losses is a multi-quarter process, and the deep valuation discount may take years to close if successful. The stock's high beta of 1.093 and lack of dividend make it unsuitable for short-term trading or income. Long-term investors can potentially benefit from the mean reversion of its sales multiple if the profitability pivot succeeds. Short-term traders face elevated risk from earnings volatility and the potential for a sharp reversal after the 77% three-month rally.